Phibro’s (PAHC) Big Acquisition Bet Just Cleared Its First Full Year
Phibro Animal Health (PAHC) reported fiscal 2026 net sales of $1.5B, adjusted EBITDA up 39% to $255M, and EPS up 48% to $3.22. The growth was driven by a recent acquisition and organic growth across segments. Guidance for fiscal 2027 expects slower growth with net sales of $1.55B-$1.6B and EBITDA of $258M-$268M. Free cash flow was $9.9M due to inventory buildup, with debt at $737.9M and a leverage ratio of 2.9x EBITDA.
How this was made
The 30-second read
Why it matters
Earnings beat may trigger short‑term buying, but debt levels and slower forward growth introduce risk.
Market read
First‑time earnings disclosure with material financial metrics for a mid‑cap specialty firm.
What to watch
Inventory buildup of $86M and potential margin pressure from the acquired portfolio.
Background
Phibro Animal Health completed its first full fiscal year after acquiring a medicated feed additive portfolio, reporting FY2026 results and FY2027 guidance.
Ticker impact
Phibro Animal Health reported FY2026 net sales of $1.5B, adjusted EBITDA $255M and raised FY2027 guidance, providing fresh earnings data.
Potential price rally of 5‑8% on earnings beat, with volatility as investors assess leverage and slower FY2027 growth.
Revenue and earnings exceeded expectations, but higher inventory and debt levels could temper enthusiasm.
Market effects
Animal health and feed additive sector may see increased investor interest as the acquisition shows integration progress.
U.S. agribusiness investors could re‑price exposure to feed additive businesses.
Limited to specialty animal health niche; broader market impact modest.
Counterpoint
Rising leverage and slowing FY2027 growth could lead to a price correction despite the earnings beat.
Key entities
- CompanyPhibro Animal Health
NASDAQ‑listed animal health and nutrition firm.
